Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Status: ENROLLING_BY_INVITATION
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: TOL2506|DRUG: Tamoxifen|DRUG: Letrozole tablets|DRUG: Anastrozole Tablets|DRUG: Exemestane Tablets
Sponsor: Tolmar Inc.